Unlocking the potential of immunotherapy in platinum-resistant ovarian cancer:rationale,challenges,and novel strategies  

作　　者：Joanna Kefas Michael Flynn 

机构地区：[1]Medical Oncology,University College London Hospitals NHS Foundation Trust,London NW12PG,UK

出　　处：《Cancer Drug Resistance》2024年第1期309-331,共23页癌症耐药(英文)

摘　　要：Ovarian cancer is a significant global health challenge,with cytoreductive surgery and platinum-based chemotherapy serving as established primary treatments.Unfortunately,most patients relapse and ultimately become platinum-resistant,at which point there are limited effective treatment options.Given the success of immunotherapy in inducing durable treatment responses in several other cancers,its potential in platinum-resistant ovarian cancer(PROC)is currently being investigated.However,in unselected advanced ovarian cancer populations,researchers have reported low response rates to immune checkpoint inhibition,and thus far,no validated biomarkers are predictive of response.Understanding the intricate interplay between platinum resistance,immune recognition,and the tumour microenvironment(TME)is crucial.In this review,we examine the research challenges encountered thus far,the biological rationale for immunotherapy,the underlying mechanisms of immune resistance,and new strategies to overcome resistance.

关 键 词：Ovarian cancer IMMUNOTHERAPY immune checkpoint inhibition immunotherapy resistance 

分 类 号：R73[医药卫生—肿瘤]